Published in Drug Week, July 30th, 2004
Important product development milestones have been achieved during the quarter and the benefits of the new business plan begin to materialize.
1) Androsonix, the non-invasive single-use acoustic biosensor, continues to bolster its potential as business opportunities arise at various levels of the patient monitoring industry, for which the global markets is estimated at more than U.S.$6 billion.
2) Positive results were announced in April 2004 for these two applications. Based on the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.